Introduction and objectives: There is increasing recognition that systemic inflammation is associated with
Introduction
Survival in patients with prostate cancer (CaP) has improved in recent years but prognosis remains poorly understood.Considerable effort has gone into identifying genetic/immunological biomarkers for cancer outcomes. However, these remain time consuming and not practical within routine clinical practice.Prostate cancer and Systemic InflammationThere is increasing recognition that systemic inflammation is associated with progression and reduced survival of prostate cancer patients 1 .Systemic inflammatory response, as evidenced by an elevated C-reactive protein (CRP), has been shown to be independently associated with poor prognosis in localized and metastatic prostate cancer 2 . Prostatic inflammatory atrophy, a candidate early preneoplastic lesion, is associated with a prominent inflammatory component.Inflammatory T-cell infiltrates accompany prostate cancer.
C reactive Protein
(CRP) is an acute-phase protein produced in the liver in response to stimulation by cytokines (IL-6, IL-1, TNF). One explanation for why CRP may identify individuals at increased risk of cancer lies in its association with chronic, mostly subclinical inflammation. The kinetic of CRP is not affected by its physiological function. The momentary plasma level therefore is anexclusive indicator of the synthesis rate and thus the inflammation.High serum levels of CRP indicates poor prognosis in prostate cancer, and it is observed with the existence of bone metastasis, raised PSA and higher gleason grade Crp was 3 times on average elevated in the cohort with bone Metastasis Crpvs Gleason Grade Table 3 Post hoc -Bonnenferroni  Gleason 2-6 vs 7 p= 0.632  2-6 vs 8-10 p= 0.01,  7 vs 8-10 p= 0.04 Logistic regression Analysis:Odds for Bone Metastasis Association of increased ALP and decreased albumin in patients with positive CRP reflected the systemic inflammatory state.
Post ADT follow up and Analysis
Patients underwent orchidectomy and selective use of bicalutamidetherapy.PSA was determined at the end of one month and then 3 monthly thereafter.PSAresponse was defined as decrease in PSA value by atleast 50% at end of first month.Proportion of patients alive at end of one year was noted. Out of 27 patients with mets 9 had died at the end of one year. Table 6 Limitations A sample size is modest for an analysis of prognostic marker in this patient population.The study was an exploratory and pilot effort and the results should be confirmed in a large cohort.Parent markers driving CRP like IL-6 are being currently explored
ANOVA

Comparison of survival curves-Patients with Metastatic disease
III. Conclusions
Higher CRP level is significantly associated with an aggressive tumor phenotype at the time of diagnosis in Carcinoma Prostate. CRP can be predictive of PSA response to therapy. CRP is a cost-effective test that can be used as one of the markers to risk-stratify men with advanced prostate cancer. CRP could prove to be a useful and readily measurable prognostic marker that could aid in clinical decision-making, patient counseling, and clinical trial design and interpretation.
